Researchers divided Sprague-Dawley rats into sham-operated, MIRI, and sevoflurane-plus-MIRI groups. They measured myocardial infarct size with 2,3,5-triphenyltetrazolium chloride staining, examined cardiac tissue with hematoxylin and eosin staining, and detected apoptotic nuclei using TUNEL staining. Quantitative reverse-transcription PCR and western blotting were used to quantify circ_SMG6 and TLR4/mTOR expression.

In the rat experiment, MIRI increased the myocardial apoptotic index, infarct size, and structural cardiac damage while elevating circ_SMG6 and TLR4/mTOR signaling. These changes were reduced with sevoflurane, although the abstract states that they were not entirely restored. In AC16 and HCM cardiomyocyte models, hypoxia-reoxygenation increased circ_SMG6, reduced cell viability, increased production of TNF-α, IL-1β, and IL-6, and increased the measured TLR4/mTOR signaling readout.

The investigators also tested circ_SMG6 overexpression and knockdown 48 hours before hypoxia-reoxygenation, with or without sevoflurane. Knockdown reversed the measured effects of hypoxia-reoxygenation, whereas overexpression further aggravated the reported injury, supporting the involvement of circ_SMG6 in the inflammatory and apoptotic responses in these cell models. Sevoflurane produced changes similar to circ_SMG6 silencing at the functional and signaling levels. These findings come from rat and cell experiments and do not establish clinical efficacy or safety in patients with myocardial infarction or MIRI; the assessment here is limited to the published abstract.

Subject of Research: Preclinical testing of sevoflurane, circ_SMG6, and TLR4/mTOR signaling in myocardial ischemia-reperfusion models

Article Title: Sevoflurane suppresses circ_SMG6 to inhibit TLR4/mTOR signaling and attenuate myocardial ischemia-reperfusion injury

Article References: Feng, M., Li, W., Chen, B., & Sun, Y. (2026). Sevoflurane suppresses circ_SMG6 to inhibit TLR4/mTOR signaling and attenuate myocardial ischemia-reperfusion injury. Molecular Biology Reports, 53(1), Article 1590. https://doi.org/10.1007/s11033-026-12758-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12758-y

Keywords: sevoflurane, myocardial ischemia-reperfusion injury, circ_SMG6, TLR4/mTOR signaling, cardioprotection, Sprague-Dawley rats, cardiomyocytes, hypoxia-reoxygenation, inflammation, apoptosis, suppresses, circ

Now, a team of researchers from the University of Szeged in Hungary and the Medical University of Vienna in Austria has reported that a synthetic version of an embryo-derived peptide may protect the heart from radiation damage while potentially preserving, and even enhancing, the anti-cancer efficacy of radiotherapy. The peptide in question is preimplantation factor, or PIF, an evolutionarily conserved 15-amino-acid peptide secreted by viable mammalian embryos. In pregnancy, PIF plays a critical role in maternal tolerance of the fetal allograft, providing integrated local and systemic immune protection, transplant acceptance, and controlled cell and organ growth. It supports embryo implantation by modulating cell proliferation and apoptosis, and it exhibits immunomodulatory, anti-inflammatory, and regenerative properties. The lessons learned from pregnancy have been translated to non-pregnancy applications, including neurologic diseases, atherosclerosis, and radiation protection, and a synthetic PIF analog containing the same amino acid sequence as the native peptide has already shown protective effects against neuroinflammation, type 1 diabetes, Duchenne muscular dystrophy, and acute radiation syndrome.

In the new study, published in Frontiers in Cardiovascular Medicine, the researchers investigated whether synthetic PIF, or sPIF, could mitigate the development of radiation-induced heart disease in rats. Adult male Sprague-Dawley rats were allocated into three experimental groups: a vehicle-treated control group, a vehicle-treated radiotherapy group receiving a single focused dose of 50 Gy to the heart, and a radiotherapy group treated with sPIF. The animals were monitored at one, three, and fifteen weeks after irradiation, reflecting the acute, subacute, and chronic phases of radiation injury. Endpoint assessments included transthoracic echocardiography, histopathology, quantitative polymerase chain reaction, Western blotting, and ultra-high-performance liquid chromatography-tandem mass spectrometry in left ventricular samples. The sPIF was administered subcutaneously at 1 mg/kg, a dose selected based on previous dose-finding experiments and on preclinical models in which 0.1 to 1 mg/kg had maximum efficacy. Treatment began daily for the first two weeks and continued twice weekly thereafter, an approach adapted from previous episodic sPIF administration in experimental autoimmune encephalomyelitis models.

The results were striking. At week three, sPIF treatment markedly reduced left ventricular overexpression of the pro-inflammatory cytokines interleukin-1 and interleukin-6, as well as the pro-survival and anti-inflammatory signal transducer and activator of transcription 3, compared with the vehicle-treated control group. This early anti-inflammatory effect presumably enabled fibrosis prevention at fifteen weeks. At the same time, the sPIF-treated radiotherapy group exhibited marked reductions in left ventricular end-diastolic and end-systolic diameters compared with the vehicle-treated control or radiotherapy groups, accompanied by increased long-axis fractional shortening. The radiotherapy-induced diastolic dysfunction observed at week three, indicated by reduced mitral annulus velocity and elevated E/e’ ratio, was markedly reduced by sPIF treatment. By week fifteen, the vehicle-treated radiotherapy group had developed concentric left ventricular hypertrophy, with significantly increased septal, posterior, and anterior wall thicknesses and relative wall thickness, as well as prolonged isovolumic relaxation time and elevated Tei index, all indicating diastolic dysfunction. sPIF treatment partially reversed these irradiation-induced changes, reflected by significant reductions in wall thicknesses and relative wall thickness, improvement in left ventricular dimensions and fractional shortening, and normalization of diastolic functional parameters.

At the cellular level, the protective effects were equally evident. At week fifteen, cardiomyocytes in the vehicle-treated radiotherapy group showed significantly increased perimeter and cross-sectional area, confirming the development of compensatory hypertrophy. Notably, there were no marked differences in cardiomyocyte perimeters and cross-sectional areas between the sPIF-treated radiotherapy group and the vehicle-treated control group at week fifteen. Molecular analysis revealed that the vehicle-treated radiotherapy group had significantly reduced expression of the adult myosin heavy chain alpha-isoform, Myh6, and a markedly higher Myh7/Myh6 ratio, indicating molecular signs of left ventricular hypertrophy development. sPIF preserved healthy adult myosin heavy chain isoform content compared with the vehicle-treated radiotherapy group. The researchers also found that sPIF treatment significantly mitigated the radiotherapy-induced reduction of left ventricular sarcoendoplasmic reticulum calcium ATPase 2a isoform, or SERCA2a, protein level at week fifteen. More preclinical studies have found a significant inverse correlation between SERCA2a gene expression and isovolumic relaxation time, indicating impaired relaxation and a potential association with heart failure with preserved ejection fraction.

Beyond hypertrophy, sPIF treatment alleviated the radiotherapy-associated cardiac fibrosis. At week fifteen, sPIF significantly reduced left ventricular expression of connective tissue growth factor and protein levels of SMAD2/3, key mediators of the transforming growth factor-beta1 pathway considered the central molecular mechanism in radiation-induced cardiac fibrosis. sPIF also significantly decreased left ventricular fibrosis at week fifteen and mitigated overexpression of A-type natriuretic peptide, a myocardial stretch marker. The antioxidant properties of sPIF were reflected in significantly reduced nitrotyrosine levels, a marker of nitro-oxidative stress, in the left ventricles after sPIF treatment compared with the vehicle-treated radiotherapy group at week fifteen. The left ventricular riboflavin content, a cofactor of the antioxidant glutathione redox cycle, remained markedly higher in the sPIF-treated radiotherapy group compared with the vehicle-treated control group. The nicotinamide adenine dinucleotide levels were markedly higher in the sPIF-treated radiotherapy group at week fifteen compared to the time-matched vehicle-treated control groups, supporting antioxidant mechanisms by increasing glutathione levels and antioxidant enzyme activity.

The cardioprotective effects of sPIF were further validated in vitro. In H9c2 cardiomyoblasts, sPIF suppressed angiotensin II-induced hypertrophy, with the cell size of sPIF-treated cardiomyoblasts being significantly smaller compared to the angiotensin II-treated group. The co-treatment with sPIF markedly counterbalanced the reduced viability of H9c2 cardiomyoblasts exposed to hydrogen peroxide-induced oxidative stress. In human ventricular cardiac fibroblasts, sPIF treatment significantly reduced collagen-I and alpha-smooth muscle actin protein expression after exposure to transforming growth factor-beta1. Scratch assays revealed a biphasic influence of transforming growth factor-beta1 on cardiac fibroblast motility, with transient enhancement of migration in the early phase after scratching but marked delay in the later phases, reflecting its canonical induction of myofibroblast differentiation, stress fiber assembly, and excessive extracellular matrix deposition. sPIF significantly supported migration in the early phase and appeared to abrogate the late inhibitory action of transforming growth factor-beta1, suggesting a role in modulating fibroblast-driven repair while mitigating maladaptive fibrosis.

Perhaps most importantly for cancer patients, sPIF did not interfere with the anti-cancer efficacy of radiotherapy. In three different human breast carcinoma cell lines, MCF-7, T47D, and MDA-MB-231, none of the tested concentrations of sPIF increased cell proliferation within 72 hours. Moreover, sPIF intensified the anti-proliferative effect of radiotherapy in breast cancer cell lines compared to radiotherapy alone. This finding is in line with previously reported sPIF-induced anti-neoplastic effects and suggests that sPIF may serve as a potential dual cardioprotective and anti-proliferative agent. The researchers hypothesized that the enhanced acute inflammation induced by sPIF in the early phase might facilitate the elimination of tissue debris and contribute to the earlier start of adaptive mechanisms and wound healing processes, mainly due to the immunomodulatory effects of the peptide. By week fifteen, sPIF appeared to prevent chronic cell death and limit harmful remodeling in radiation-induced heart disease.

Mechanistically, sPIF primarily targets protein disulfide isomerase/thioredoxin and heat shock proteins, thereby reducing oxidative stress and protein misfolding and preventing cellular damage. These targeted protective mechanisms are key in addressing radiotherapy-induced organ damage. sPIF has been reported as a robust immunomodulator and cellular protector in acute radiation syndrome by binding to innate immune cells such as macrophages and neutrophils, suppressing inflammatory mediators such as tumor necrosis factor-alpha and inducible nitric oxide synthase, and promoting a tolerant, balanced immune profile. It regulates innate immunity by blocking voltage-gated potassium channels, thereby reducing overactivity of neutrophils and natural killer cells without broad immune depletion, and selectively tunes adaptive immunity by inhibiting pro-inflammatory pathways like IL-23 and IL-17a-mediated signaling, thereby reducing toxicity but preserving infection defense. Notably, sPIF has been tested in Fast Track FDA human clinical trials for autoimmune disease, demonstrating safety and the absence of adverse drug-drug interactions, and has received FDA orphan drug designation for acute radiation syndrome.

The authors recognize several limitations of the current study. Significant differences exist in the pathomechanisms of experimental and clinical radiation-induced heart disease, comprising species-, sex-, and age-related attributes, as well as the absence of tumors, atherosclerosis, and other cardiovascular risk factors. To avoid cycle- and hormone-dependent protective effects, the researchers opted to use only male rats. Moreover, the therapeutic effects of sPIF were tested in a healthy adolescent rat model, which represents an additional limitation. Single-dose irradiation models differ from clinical radiotherapy, which typically uses multiple smaller fractions, and single doses can exaggerate and accelerate tissue damage in preclinical models. The researchers acknowledge that findings from single-dose models might have limited translational relevance, although they note that in modern radiotherapy practice, very high doses are used in stereotactic radiosurgery, and their findings may also apply to that field. Animal models incorporating both sexes, mediastinal tumors or breast cancer, cardiovascular risk factors, comorbidities, and advanced age would more closely recapitulate the clinical setting of radiation-induced heart disease.

Despite these limitations, the study identified sPIF as a novel, promising, druggable candidate for preventing and improving the signs of radiation-induced heart disease. The researchers emphasize that the exact initiating targets and upstream signaling mechanisms of sPIF in radiation-induced heart disease remain unexplored, and that transforming growth factor-beta/SMAD signaling and SERCA2a preservation are correlative biomarkers rather than definitive proof of direct mechanisms. Future preclinical studies could clarify the cardioprotective and anti-neoplastic mechanisms of sPIF and its direct mechanistic links to nitro-oxidative stress, inflammation, fibrosis, and apoptosis in radiation-induced heart disease. Given its effectiveness in preclinical models, sPIF could be a valuable addition to cancer radiotherapy regimens and warrants further exploration of its safety and efficacy in human trials. For the growing population of cancer survivors living with the cardiovascular consequences of their life-saving treatment, the prospect of a pregnancy-derived peptide that shields the heart without weakening the anti-cancer beam represents a genuinely new direction in cardio-oncology.

Subject of Research: Cardio-Oncology

Article Title: Synthetic preimplantation factor ameliorates the severity of radiotherapy-induced heart disease in a rat model

Article References: Kovács, M. G., Antunes Goncalves, A. I., Varga, Z., Losonczi, R., Kupecz, K., Volford, D., Pósa, S. P., Minorics, R., Galla, Z., Zins, K., Sejben, A., Kriston, A., Kovács, F., Horváth, P., Monostori, P., Cserni, G., Zupkó, I., Podesser, B. K., Barnea, E. R., … Sárközy, M. (2026). Synthetic preimplantation factor ameliorates the severity of radiotherapy-induced heart disease in a rat model. Frontiers in Cardiovascular Medicine, 13, Article 1946843. https://doi.org/10.3389/fcvm.2026.1946843

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1946843

Keywords: radiation-induced heart disease, synthetic preimplantation factor, cardioprotection, radiotherapy, cardio-oncology, cardiac fibrosis, diastolic dysfunction, left ventricular hypertrophy, nitro-oxidative stress, breast cancer, Synthetic, preimplantation

At the center of the review is the concept of cardioprotection, defined decades ago as any intervention that limits myocardial injury, and most vividly demonstrated by ischemic conditioning. When heart tissue is briefly deprived of blood and then reperfused, the paradoxical surge of oxygen can inflict as much damage as the original ischemia, a phenomenon known as ischemia-reperfusion injury. The cell responds to this threat by activating a set of overlapping survival circuits. The best characterized is the Reperfusion Injury Salvage Kinase, or RISK, pathway, which funnels signals through phosphatidylinositol 3-kinase, Akt, and extracellular signal-regulated kinases to inhibit mitochondrial permeability transition pore opening and suppress programmed cell death. Pharmacological activation of this cascade, including through insulin-mediated PI3K/Akt/mTOR signaling, has been explored extensively as a route to clinical cardioprotection, although translation from bench to bedside has proved challenging.

A second major arm of defense is the Survivor Activating Factor Enhancement, or SAFE, pathway, which is engaged by cytokines such as interleukin-6 and signal transduced through the JAK-STAT axis. First described by Sébastien Lecour in 2009, the SAFE pathway was initially viewed as a parallel route to RISK, but subsequent work has shown that the two circuits converge on common end points: preservation of mitochondrial integrity, inhibition of apoptosis, and limitation of infarct size. The review also highlights protein kinase C epsilon, an isoform that resides at both sarcomeres and mitochondria and whose activation forms protective signaling complexes detectable by proteomic analysis. Its counterpart, protein kinase C delta, tends to exert opposing, harmful effects during reperfusion, illustrating the exquisite isoform specificity of cardiac survival signaling.

The nitric oxide axis provides a third route to protection. Signaling through NO/cGMP/PKG, this pathway modulates calcium handling, mitochondrial respiration, and reactive oxygen species generation. Recent strategies have focused on novel ways of activating protein kinase G, including soluble guanylate cyclase stimulators, reflecting a recognition that cGMP sits at a central node of the cardioprotective network. Mitogen-activated protein kinase signaling, by contrast, plays a dual role that the literature has famously characterized as angels versus demons: certain branches such as ERK contribute to survival, while stress-activated branches like p38 and JNK can amplify injury depending on the timing and context of their activation.

What ultimately decides the fate of the ischemic heart is the mitochondrion. The review devotes sustained attention to mitochondrial dysfunction as both a driver and a target of injury. Reactive oxygen species produced by damaged electron transport chains oxidize proteins and lipids, trigger the opening of the mitochondrial permeability transition pore, and activate the NLRP3 inflammasome, an intracellular sensor that amplifies sterile inflammation. The ROS/NLRP3 axis has been implicated not only in ischemia-reperfusion injury but also in chemotherapy-induced cardiotoxicity, as demonstrated in models of doxorubicin exposure. Inflammatory processes following myocardial infarction are dynamic, with immune cells playing repair roles early and remodeling roles later, which means therapeutic interference must be timed with precision. Oxidative stress, necrotic transmission, and self-destruction through apoptosis and autophagy form an interlocking web that the review maps against the protective signaling pathways attempting to hold the line.

Against this mechanistic backdrop, the authors survey the diagnostic landscape. Cardiac troponins I and T remain the cornerstone of myocardial infarction diagnosis under the Fourth Universal Definition, offering high sensitivity and specificity for myocyte injury. Creatine kinase-MB, once the conventional marker, has been largely superseded by troponins but retains utility in specific settings, including reinfarction detection. Natriuretic peptides, BNP and NT-proBNP, serve a different purpose: they reflect wall stress and are indispensable for diagnosing and managing heart failure, as codified in recent guidelines from the European Society of Cardiology, the Heart Failure Society of America, and the Japanese Heart Failure Society. Inflammatory markers such as C-reactive protein, interleukin-6, and tumor necrosis factor alpha add prognostic texture, linking the pathological inflammation described at the molecular level to measurable clinical risk.

The most forward-looking portion of the review concerns non-coding RNAs. MicroRNAs such as miR-21, miR-486-5p, and miR-126 have emerged as both regulators and reporters of cardioprotective signaling. A systematic review and network analysis of microRNAs involved in protection against ischemia-reperfusion injury found extensive involvement of redox signaling, tying these small molecules directly to the ROS-centered pathology described above. Long non-coding RNAs add another layer of regulation, and exosomes, the nanoscale vesicles that carry RNA and protein cargo between cells, have been proposed both as biomarkers of early cardiac damage and as delivery vehicles for therapy. The paracrine mechanisms through which mesenchymal stem cells protect the infarcted heart are now understood to operate substantially through such extracellular vesicles.

Emerging molecular signatures extend beyond single markers to genome-wide expression programs. Studies of biomechanically stretched cardiomyocytes have identified stretch-specific gene programs, while work on nuclear factor kappa B has uncovered a cardioprotective gene battery in which regulation of heat shock proteins contributes to survival after permanent coronary occlusion. Proteomic and metabolomic analyses of the cardiac extracellular matrix and circulating metabolites promise multiscale biological insight, and systems medicine approaches aim to enable precision cardiology by integrating multi-omics data with clinical phenotypes. Novel markers such as galectin-3 and soluble ST2 have already entered the prognostic toolkit for heart failure, complementing natriuretic peptides in risk evaluation and therapy monitoring.

The review also connects molecular cardioprotection to lifestyle physiology. Caloric restriction has been shown to attenuate inflammatory responses to ischemia-reperfusion injury, reduce oxidative damage to mitochondrial proteins, activate SIRT1-dependent pathways, and produce a distinct cardioprotective gene signature detectable within days of adoption. Exercise training induces a preconditioning-like phenotype through many of the same RISK and SAFE convergent mechanisms, and intermittent fasting is being explored through the lens of circadian rhythm biology. Even remote ischemic conditioning, in which brief cycles of limb ischemia protect the distant heart, has been tested in large randomized trials such as CONDI-2/ERIC-PPCI, underscoring both the promise and the difficulty of translating robust experimental protection into consistent clinical benefit, a challenge famously framed by Gerd Heusch in The Lancet.

What emerges from this synthesis is a portrait of the heart as an organ whose fate after injury hinges on a small number of interconnected molecular decisions: whether survival kinases dominate stress kinases, whether mitochondria remain sealed, whether inflammasomes stay quiescent, and whether protective RNAs are deployed in time. By aligning the classical biomarkers with emerging molecular signatures, the authors argue for a framework in which risk evaluation, early detection, and personalized therapy plans are grounded in mechanism rather than convention. The hope is that such an integrated perspective, bridging signaling physiology with clinical application, will accelerate the long-sought goal of precise cardiovascular treatment and meaningfully improve patient outcomes in the world’s deadliest disease.

Subject of Research: Molecular mechanisms of cardioprotection and cardiac biomarkers in cardiovascular disease

Article Title: Molecular mechanisms of cardioprotection: biomarkers, signaling pathways, and emerging molecular signatures in cardiovascular disease

Article References: Amir, M., Khalid, M., Zaheer, L., Nazar, S., Khursheed, M. A., Hussain, M., & Ahmad, T. (2026). Molecular mechanisms of cardioprotection: biomarkers, signaling pathways, and emerging molecular signatures in cardiovascular disease. Molecular Biology Reports, 53(1), Article 1735. https://doi.org/10.1007/s11033-026-12872-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12872-x

Keywords: cardioprotection, myocardial infarction, biomarkers, cardiac troponins, natriuretic peptides, RISK pathway, SAFE pathway, microRNAs, mitochondrial dysfunction, reactive oxygen species, NLRP3 inflammasome, ischemia-reperfusion injury

The problem, as described by a team of researchers led by Di Jiang, Ruixuan He, Bowen Yang and Jianlin Shi of the Shanghai Institute of Ceramics at the Chinese Academy of Sciences, is one of dilution and dispersion. Exosomes released by stressed endothelial cells do not queue politely outside the damaged region of myocardium. Once they enter the circulation, they distribute systemically, spreading throughout the body and exposing the injured heart to only a small fraction of the protective cargo that was released on its behalf. The result is a response that is diffuse, short-lived and therapeutically wasted — a signal that is sent but barely received.

The team’s solution is an unusual twist on nanomedicine. Rather than loading synthetic nanoparticles with drugs, they engineered a systemically administered nanosystem whose job is to intercept the body’s own endothelial exosomes in the bloodstream and shepherd them to where they are needed most. The system is designed to capture circulating endothelial exosomes, mediate their transvascular relocalization — that is, their movement across the vessel wall and into the injured tissue — and then promote their delivery to cardiomyocytes, the contractile muscle cells of the heart. In effect, the nanoparticles act as a biological courier service, redirecting the heart’s native distress communications back to the heart itself.

The concept inverts a dominant paradigm in drug delivery. For decades, the field has focused on encasing therapeutic molecules inside synthetic carriers and fighting the body’s delivery barriers to get those cargoes to a target organ. Here, the cargo is entirely endogenous: the exosomes, with their natural complement of angiocrine signaling molecules, are produced by the patient’s own endothelium. The nanosystem contributes only routing and localization. The therapeutic payload remains the body’s own, which means the approach enhances the reception of native angiocrine signals at the injured myocardium rather than introducing foreign biology. That distinction matters for both safety and for the fidelity of the message being delivered, since the exosome cargo reflects the actual physiological state of the injured vasculature.

To test the strategy, the researchers turned to a murine model of acute cardiac ischemia, using male mice in which blood supply to a region of the heart was compromised. In this setting, the nanosystem was administered systemically — an important practical feature, because it means the treatment does not require direct injection into the heart or the coronary arteries. Once in the circulation, the system carried out its three-step function: capture of circulating endothelial exosomes, transvascular shuttling into the ischemic myocardium, and hand-off to cardiomyocytes within the damaged tissue.

The outcomes reported in the study track the intervention’s logic step by step. Exposure of the injured myocardium to endothelial exosomes increased, confirming that the relocalization mechanism works in living animals rather than only in laboratory dishes. Cardiomyocyte survival improved, indicating that the redirected exosomes were not merely accumulating in the tissue but were actively delivering protective signaling to the cells that matter. And cardiac function was preserved, the ultimate functional readout: the hearts of treated animals retained more of their pumping capacity than would otherwise be expected after an ischemic insult. Taken together, the results suggest that the intervention converts the body’s originally diffuse, short-lived angiocrine response into a sustained, organ-specific therapeutic exposure.

What makes this finding conceptually significant is the reframing of exosomes themselves. In much of the biomedical literature, exosomes are treated as drug delivery vehicles in waiting — naturally derived nanoparticles that could be loaded with RNA, proteins or small molecules and steered toward tumors or inflamed tissues. The Shanghai team treats them instead as cargo worth protecting in their own right. Endothelial exosomes under ischemic stress are not inert carriers; they are the message. Their contents are calibrated by the very cells that sense the injury, potentially encoding a physiologically appropriate cocktail of protective signals that no artificial formulation has yet matched. The engineering challenge is not to replicate that message but to make sure it arrives.

This reorientation also speaks to a broader frustration in cardiovascular medicine. Acute ischemic events — heart attacks foremost among them — remain a leading cause of death worldwide, and the window for saving endangered cardiomyocytes is narrow. Many experimental cardioprotective strategies that succeeded in animal models have struggled in clinical translation, in part because delivering sufficient protective agent to the jeopardized myocardium quickly and safely is extraordinarily difficult. A strategy that amplifies the effectiveness of signals the body is already producing sidesteps some of the pharmacological hurdles of new drug development, though it introduces its own questions about manufacturing, consistency and control of a biological delivery system.

The authors emphasize the male mouse context of their findings, and that restriction is worth taking seriously. Sex differences in exosome biology, endothelial signaling and response to ischemia are well documented across cardiovascular research, and results obtained in male animals do not automatically generalize to females. The path from a mouse model of induced ischemia to human heart attack patients is long, and it will require answers to questions the current study does not address: how the nanosystem behaves at larger scale, how it is cleared, what happens to exosomes captured from organs other than the heart, and whether the relocalization mechanism can be tuned to different vascular beds. None of these caveats diminishes the central demonstration — that circulating endothelial exosomes can be captured, redirected and put to work as therapy — but they frame the distance still to travel.

Still, the conceptual payload of the study extends beyond cardiology. Angiocrine signaling — the dialogue between vascular endothelium and the organs those vessels serve — is increasingly recognized as a master regulator of tissue repair, not only in the heart but in the brain, liver, kidney and lung. If a nanosystem can relocalize circulating endothelial exosomes toward the ischemic myocardium, the same architectural idea could in principle be adapted to other injuries in which the endothelium responds helpfully but the message gets lost in the bloodstream. The Shanghai team’s work, supported by the National Natural Science Foundation of China and published open access, offers a proof of concept for a new therapeutic category: not drugs, not gene therapy, not even engineered exosomes, but the targeted redistribution of the body’s own emergency communications. In a field crowded with attempts to out-engineer biology, the most elegant move may sometimes be to simply deliver what biology already tried to send.

Subject of Research: A nanosystem that relocalizes endothelial exosomes to enhance angiocrine cardioprotection in ischemic myocardium

Article Title: A nanosystem manipulates angiocrine signaling for cardioprotection in male mice by relocalizing endothelial exosomes

Article References: Jiang, D., He, R., Yang, B., & Shi, J. (2026). A nanosystem manipulates angiocrine signaling for cardioprotection in male mice by relocalizing endothelial exosomes. Nature Communications. https://doi.org/10.1038/s41467-026-78706-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78706-3

Keywords: nanomedicine, exosomes, angiocrine signaling, cardioprotection, endothelial cells, myocardial ischemia, cardiomyocytes, drug delivery, Nature Communications, cardiovascular biology, nanosystem, heart disease

The research team, led by Nour Elhouda Daoudi of Mohammed First University in Oujda, Morocco, together with collaborators at King Saud University and elsewhere, set out to answer a question that has lingered around this celebrated oil: does the heat of roasting destroy the very molecules that make argan oil medicinally interesting? Roasting is known to alter the chemical composition of vegetable oils, particularly their phenolic compounds, tocopherols, and antioxidant capacity. If heat-sensitive bioactives were the key to argan oil’s benefits, traditionally roasted oil might be nutritionally inferior to oil pressed from raw kernels. The new results suggest otherwise.

To test the question rigorously, the researchers harvested argan fruits from the Agadir region of Morocco in February 2019 and split the seeds into two batches. One batch was pressed raw to yield unroasted argan oil, with an extraction yield of 12.50 percent. The other was roasted at 100 degrees Celsius for roughly 20 minutes with continuous mixing to prevent localized overheating, then pressed to yield roasted oil at a much higher yield of 28.49 percent. Both oils were extracted mechanically, without solvents, using a cold-press expeller, then filtered and stored in opaque glass bottles at 4 degrees Celsius until use. Gas chromatography coupled with mass spectrometry, drawing on previously published characterization work, confirmed that both oils were dominated by unsaturated fatty acids, chiefly oleic and linoleic acids, alongside palmitic and stearic acids, with the unroasted oil showing a slightly higher ratio of unsaturated to saturated fats. One compound, the hydrocarbon heptadecane 2,6-dimethyl, appeared only in the roasted oil.

The biological test bed was a classic one: adult Wistar rats in which diabetes was induced by streptozotocin, a DNA-alkylating toxin originally isolated from the bacterium Streptomyces achromogenes that selectively destroys insulin-producing pancreatic beta cells. Thirty rats were divided into five groups of six: healthy controls, untreated diabetic controls, diabetic rats given the frontline drug metformin at 250 milligrams per kilogram of body weight per day, and two diabetic groups receiving either roasted or unroasted argan oil by daily oral gavage at 2 milliliters per kilogram of body weight. After six weeks of treatment, the researchers collected blood, liver, and heart tissue for a battery of biochemical assays and histopathological examination.

The metabolic results were striking. Untreated diabetic rats had blood glucose levels above 5 grams per liter, more than five times the normal value of roughly 0.94 grams per liter. Six weeks of treatment with either version of the oil drove glucose down to about 1.07 to 1.09 grams per liter, statistically indistinguishable from the metformin group and approaching normal. The oils also reversed the swelling of the liver that accompanies diabetic injury, restoring relative liver weight to near-normal values. In the lipid arena, both oils significantly lowered the elevated triglycerides, total cholesterol, LDL cholesterol, and VLDL cholesterol that streptozotocin had driven upward, while raising the depressed HDL cholesterol back toward healthy levels. Total cholesterol and HDL values in the treated animals were statistically comparable to those of the normal controls.

The liver, an organ that bears a heavy burden in diabetes, showed clear signs of recovery. Streptozotocin poisoning had sent the liver enzymes ALT, AST, and LDH surging into the bloodstream, a hallmark of hepatocyte damage, and had elevated both direct and total bilirubin, signaling impaired bile excretion. Treatment with either roasted or unroasted oil brought ALT and LDH back to normal and significantly reduced bilirubin, although AST remained somewhat elevated. Notably, metformin, for all its metabolic benefits, failed to significantly improve these liver markers in this model, and the authors caution that this may reflect the specific experimental conditions rather than an absence of hepatoprotective potential. The oils also restored hepatic glycogen, the stored form of glucose that insulin depletion drains from the liver, from a diabetic low of 0.64 milligrams per gram of tissue back to the normal value of about 1.01 milligrams per gram, likely by supporting the reactivation of glycogen synthesis.

Oxidative stress, the destructive accumulation of reactive oxygen species that underlies much diabetic tissue damage, was substantially tamed. Malondialdehyde, or MDA, the standard marker of lipid peroxidation, was sharply elevated in the livers and hearts of diabetic rats. Both oils cut MDA levels dramatically, and in the heart the values returned fully to normal, while in the liver they fell significantly though not completely. The antioxidant defenses themselves were replenished: reduced glutathione, depleted by diabetes, rebounded in both organs, and catalase, the enzyme that converts hydrogen peroxide into water and oxygen, recovered in the liver and improved in the heart. In a telling contrast, metformin did not significantly restore glutathione in this experiment, whereas both argan oils did.

Under the microscope, the protective story became vivid. Hematoxylin-eosin staining revealed that untreated diabetic livers were riddled with lipid droplets and patches of hepatocyte necrosis, while hearts showed disordered cardiac fibers and damaged cardiomyocyte nuclei. Masson’s trichrome staining, which dyes collagen blue, exposed extensive fibrosis, the scarring that stiffens organs and, in the heart, raises the risk of arrhythmias and heart failure. Treatment with either oil prevented the lipid droplets, limited collagen deposition in the portal triads of the liver and the myocardium of the heart, and preserved tissue architecture far better than untreated diabetes allowed. Metformin reduced collagen but did not fully normalize it. Quantification of collagen area confirmed that both oils significantly blunted fibrosis in both organs.

What explains this pharmacological breadth? The authors point to argan oil’s rich cargo of phytosterols, which compete with cholesterol for incorporation into intestinal micelles and thereby limit cholesterol absorption, and to its abundance of unsaturated fatty acids, which modulate hepatic lipid metabolism and oxidation. Its tocopherols and phenolics neutralize the free radicals that streptozotocin unleashes, easing the oxidative burden on liver and heart alike. Crucially, the comparison between roasted and unroasted oils showed no significant differences in glycemia, lipid profile, liver enzymes, bilirubin, glycogen, oxidative stress markers, or collagen deposition. The heat of traditional roasting, the study concludes, does not strip the oil of the molecules responsible for these effects, meaning that the aromatic, culinary-grade oil retains its medicinal character.

The findings come with caveats that the authors acknowledge candidly. Six animals per group is a small sample, the streptozotocin rat model cannot fully recapitulate human diabetes, and a single dose over six weeks says nothing about long-term outcomes or dose-response relationships. Clinical trials in humans remain the necessary next step, along with molecular studies to pin down the precise pathways involved. Still, with the International Diabetes Federation projecting 784 million people living with diabetes by 2040, and diabetic cardiomyopathy and liver disease among the most feared complications, the idea that a traditional food oil, roasted or not, could complement existing therapies is an appealing one. For the women of Morocco’s argan cooperatives who have roasted kernels by hand for centuries, science has now offered a measure of vindication: the heat that creates the flavor does not destroy the medicine.

Subject of Research: Hepatoprotective and cardioprotective effects of roasted versus unroasted argan oil in streptozotocin-induced diabetic rats

Article Title: Effects of Roasting on the Antioxidant and Lipid‐Modulating Activities of Argania spinosa Oil Under Diabetic Conditions

Article References: Daoudi, N. E., Aziz, M., Choukri, M., Younous, Y. A., Bouallegue, A., Elossaily, G. M., Gaafar, A.-R. Z., Said, M. A., Ali, H., & Bnouham, M. (2026). Effects of Roasting on the Antioxidant and Lipid‐Modulating Activities of Argania spinosa Oil Under Diabetic Conditions. Food Science & Nutrition, 14(10), Article e72441. https://doi.org/10.1002/fsn3.72441

Image Credits: AI Generated

DOI: 10.1002/fsn3.72441

Keywords: argan oil, Argania spinosa, diabetes, oxidative stress, hepatoprotection, cardioprotection, roasting, lipid profile, streptozotocin, antioxidants, fibrosis, Morocco

MAMs are not organs in the conventional sense but specialized zones of close physical contact between the endoplasmic reticulum, the cell’s protein and lipid factory, and mitochondria, its power plants. The two membranes are held roughly 10 to 25 nanometers apart by protein tethers, including the mitofusin 2 bridge, the voltage-dependent anion channel VDAC1 on the mitochondrial outer membrane paired with the inositol trisphosphate receptor IP3R on the ER via the chaperone GRP75, and additional connectors such as PTPIP51, VAPB and ATAD3A. This architecture is far more than scaffolding. At these contact points the cell exchanges calcium from ER stores into mitochondria, synthesizes and shuttles phospholipids, coordinates mitochondrial fission through the dynamin-related protein Drp1, and monitors mitochondrial quality through mitophagy pathways involving PINK1 and Parkin. In cardiomyocytes, which beat billions of times over a lifetime and depend on relentless ATP production, the integrity of these contacts is a matter of survival.

The review’s central mechanistic claim is that during ischemia and especially reperfusion, MAMs become the staging ground for a signaling cascade that runs from ER stress to mitochondrial catastrophe. The key player is PERK, the protein kinase R-like endoplasmic reticulum kinase, an ER stress sensor that sits within MAMs. When reperfusion floods the cell with calcium and misfolded proteins accumulate, PERK activates and phosphorylates eukaryotic initiation factor 2α, triggering the unfolded protein response and the transcription factor ATF4, which in turn induces the pro-death protein CHOP. This PERK-MAM axis drives mitochondrial reactive oxygen species production, and the resulting oxidative burden pushes cardiomyocytes toward ferroptosis, an iron-dependent form of regulated cell death defined by the catastrophic peroxidation of polyunsaturated fatty acids in cellular membranes.

Ferroptosis is biochemically distinct from apoptosis and necrosis, and the review places MAMs at the heart of its lipid supply chain. The phospholipid remodeling that generates vulnerable peroxidation substrates depends on enzymes such as acyl-CoA synthetase 4, or ACSL4, and lipoxygenases including ALOX15, which incorporate polyunsaturated fatty acids like arachidonic acid into membrane phosphatidylethanolamine. Critically, the synthesis of phosphatidylethanolamine itself occurs at MAMs, where phosphatidylserine generated in the ER is transferred to mitochondria and decarboxylated by phosphatidylserine decarboxylase. In other words, the very contact sites that manufacture the cell’s membranes also determine whether those membranes become fuel for ferroptotic destruction. When the antioxidant defense system fails, particularly glutathione peroxidase 4, or GPX4, which normally repairs lipid hydroperoxides, the accumulated peroxides rupture membranes and kill the cell.

The calcium dimension adds another layer of lethality. Reperfusion delivers a surge of calcium that overloads mitochondria through the MAM-adjacent calcium uniporter MCU, promoting opening of the mitochondrial permeability transition pore, collapse of the membrane potential and further reactive oxygen species generation. Excessive MAM tethering, the review notes, can worsen this calcium overload, while excessive detachment disrupts energy metabolism and mitochondrial dynamics. The therapeutic window therefore appears to be narrow and precisely regulated: a healthy heart needs MAMs neither too tight nor too loose. Disruption of this balance also impairs mitochondrial fission and fusion, and the review highlights roles for FUNDC1-mediated mitophagy and sirtuins such as SIRT1 and SIRT3 in maintaining mitochondrial quality at these contact sites.

Perhaps the most clinically ambitious section of the review connects acute reperfusion injury to chronic ventricular remodeling, the slow process of scarring, dilatation and heart failure that follows myocardial infarction. The authors argue that MAM damage is not a one-off event but a continuous pathological thread. Persistent MAM dysfunction in surviving cardiomyocytes, cardiac fibroblasts and cardiac microvascular endothelial cells sustains lipid peroxidation, inflammatory signaling through pathways such as TLR4, NF-κB and the JNK and MAPK cascades, and maladaptive fibroblast activation. Ferroptotic death of cardiomyocytes releases damage signals and iron that further fuel fibrosis, while endothelial MAM dysfunction impairs microvascular recovery. By classifying the experimental evidence into cardiac ischemia-reperfusion models, permanent infarction models, post-infarction remodeling models and non-cardiac mechanistic systems, the authors attempt to make clear which findings speak to acute injury and which to long-term remodeling.

On the therapeutic front, the review surveys an unusually broad arsenal organized around what it calls the MAMs-lipid metabolism-ferroptosis axis. Small-molecule ferroptosis inhibitors such as ferrostatin-1 and liproxstatin-1, which intercept lipid radicals, have shown cardioprotective effects in experimental reperfusion models, as have mitochondria-targeted antioxidants like Mitoquinone, or MitoQ. Modulators of ER-mitochondrial tethering, including agents that stabilize the sigma-1 receptor at MAMs, represent a more structurally targeted approach. Natural active ingredients, including thymoquinone from black seed oil and various traditional Chinese medicine compounds, are reported to act through antioxidant, anti-ferroptotic and MAM-stabilizing mechanisms, often by activating the Nrf2 antioxidant pathway or preserving GPX4 activity. The review also discusses gene therapy strategies aimed at restoring mitofusin 2 expression or silencing ACSL4, and emerging nano-delivery systems designed to carry ferroptosis inhibitors specifically to the ischemic myocardium.

The translational logic is compelling because it addresses a gap that existing therapies cannot close. Reperfusion strategies such as primary percutaneous coronary intervention save lives but do nothing to prevent the downstream cell death programs they inadvertently ignite, and no approved drug currently protects the human heart against MIRI. A therapy that simultaneously dampens acute ferroptotic death during reperfusion and limits the chronic remodeling that leads to heart failure would be genuinely transformative, and the MAM platform offers a mechanistic rationale for why a single intervention might achieve both. The authors frame their work as providing a systematic theoretical basis and translational direction for such dual-benefit myocardial protective therapies.

Important caveats remain, and the review is candid about them. As a narrative review based on literature in PubMed and Web of Science through March 2026, it did not apply formal systematic screening, and much of the evidence it synthesizes comes from cell culture and animal models whose fidelity to human reperfusion injury varies. The precise dose-response relationship between MAM tethering and injury, the identity of the best drugable nodes in the PERK-mtROS-ferroptosis cascade, and the safety of chronically altering organelle contacts in a beating heart all require direct experimental testing. Biomarkers that would allow clinicians to measure MAM dysfunction or ferroptotic burden in patients are still lacking. Yet the sheer convergence of calcium biology, lipid chemistry and cell death signaling at these nanometer-scale contact points makes them one of the most intriguing targets in cardiovascular medicine, and this review offers the clearest map yet of how a structural curiosity of cell biology could become the key to protecting the reperfused heart.

Subject of Research: The role of mitochondria-associated endoplasmic reticulum membranes in myocardial ischemia-reperfusion injury, lipid metabolism and ferroptosis

Article Title: Mitochondria-associated endoplasmic reticulum membranes in myocardial ischemia-reperfusion injury: integrating lipid metabolism and ferroptosis

Article References: Guan, X., Cheng, H., Li, Z., Li, J., Wen, N., & Wang, L. (2026). Mitochondria-associated endoplasmic reticulum membranes in myocardial ischemia-reperfusion injury: integrating lipid metabolism and ferroptosis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09052-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09052-7

Keywords: MAMs, myocardial ischemia-reperfusion injury, ferroptosis, lipid metabolism, mitochondria, endoplasmic reticulum, ventricular remodeling, PERK, reactive oxygen species, cardioprotection, GPX4, therapeutic targets

The research, led by Guang-qiu Ren and Jing Yang at Puyang Medical College with colleagues from North Henan Medical University and Xinxiang Central Hospital, focused on a compound extracted from the roots of plants in the Boraginaceae family, long used in traditional Chinese medicine. Shikonin is a naphthoquinone, a class of molecules defined by a quinone ring structure that gives them distinctive redox chemistry. Previous work has shown that shikonin possesses antioxidant properties and can protect mitochondria, the energy-producing organelles that are among the first casualties of doxorubicin toxicity. Earlier studies from the same group also found that shikonin alleviates vascular aging in rats fed a high-fat diet by inhibiting oxidative stress and mitochondrial damage, which encouraged the team to test whether similar mechanisms operate in the chemotherapy-injured heart.

To model the clinical problem, the researchers established a chronic doxorubicin-induced cardiotoxicity model in male Sprague-Dawley rats. Doxorubicin was administered to induce the kind of progressive cardiac injury seen in patients undergoing repeated chemotherapy cycles. The animals were then treated with either shikonin or captopril, an established cardiovascular drug used here as a comparator. The team assessed cardiac function using echocardiography, examined myocardial structure and collagen deposition with histological and fluorescence staining, and measured oxidative stress markers, mitochondrial function, and senescence-associated changes through biochemical assays and Western blotting. This multi-pronged approach allowed them to connect whole-organ outcomes, such as pumping performance, with molecular events happening inside individual heart cells.

The results painted a clear picture of what doxorubicin does to the heart over time. Echocardiography revealed impaired cardiac function in the treated rats, while histological analysis showed disruption of myocardial structure and a marked increase in collagen deposition, the hallmark of fibrosis. At the biochemical level, doxorubicin tipped the heart’s redox balance toward oxidative stress, depolarized the mitochondrial membrane potential, and promoted myocardial senescence, the state in which heart muscle cells stop dividing but remain metabolically active and secrete inflammatory and fibrotic signals. Western blotting showed that doxorubicin increased the expression of DRP1 and FIS1, two proteins that drive mitochondrial fission, along with elevated levels of phosphorylated p53 and p21, key components of the senescence signaling pathway.

When shikonin was added to the treatment regimen, these alterations were substantially ameliorated. Cardiac function improved, myocardial structure was better preserved, and collagen accumulation was reduced. The compound restored redox balance, stabilized the mitochondrial membrane, and dampened the senescence program, lowering the expression of DRP1, FIS1, phosphorylated p53, and p21. The comparison with captopril is notable because it situates shikonin’s effects alongside an established cardioprotective agent, suggesting that the natural compound operates in a clinically meaningful therapeutic range rather than producing only marginal biochemical shifts.

To probe the mechanism more directly, the researchers turned to H9c2 cardiomyoblasts, a rat-derived cell line widely used to study cardiac injury in vitro. They performed complementary loss- and gain-of-function experiments targeting DRP1, the dynamin-related protein that orchestrates mitochondrial fission. When the team knocked down DRP1 in doxorubicin-treated cells, the intervention mimicked several of shikonin’s protective effects, supporting the idea that excessive mitochondrial fission is a central driver of chemotherapy-induced cardiac damage. Conversely, when DRP1 was overexpressed, it partially reversed shikonin’s suppression of mitochondrial superoxide accumulation and senescence-associated changes, indicating that DRP1 sits downstream of, or in a feedback loop with, the pathways shikonin modulates.

These findings place mitochondrial dynamics at the center of the doxorubicin cardiotoxicity story. Mitochondria exist in a dynamic equilibrium between fission, which divides damaged organelles for degradation, and fusion, which mixes contents and preserves function. When this balance is disrupted, as happens when DRP1 and FIS1 are upregulated, fragmented mitochondria accumulate, their membranes depolarize, and they leak reactive oxygen species. In cardiomyocytes, which are almost entirely dependent on mitochondrial oxidative phosphorylation and have very limited capacity for self-renewal, this cascade is particularly destructive. The resulting oxidative stress damages proteins, lipids, and mitochondrial DNA, and it activates the p53/p21 axis that pushes cells into senescence.

The senescence component of the study is especially significant for the long-term outlook of cancer survivors. Senescent cells in the heart do not simply sit quietly; they acquire a senescence-associated secretory phenotype, releasing inflammatory cytokines, growth factors, and matrix-remodeling enzymes that promote fibrosis and further dysfunction. By showing that shikonin reduces phosphorylated p53 and p21 expression alongside its mitochondrial effects, the study links two processes, mitochondrial dysregulation and cellular senescence, that are often studied separately but appear to be tightly coupled in the injured myocardium. The fibrotic remodeling that shikonin attenuated in the rat hearts is plausibly a downstream consequence of this senescent, pro-fibrotic signaling environment.

Shikonin itself is an intriguing therapeutic candidate with a growing portfolio of reported actions. Beyond its antioxidant and mitochondrial protective properties highlighted in this study, prior research has documented its ability to attenuate oxidative injury in colon-derived cell lines, activate the Nrf2-ARE antioxidant signaling pathway to protect cochlear neurons from degeneration, and exert antitumor effects against colon cancer. Its pharmacokinetics, toxicology, and pharmaceutical development have been reviewed in recent literature, and the compound has even entered clinical trial discussions. The new study adds cardioprotection during chemotherapy to this list, a use case that would be particularly attractive if shikonin could be co-administered with doxorubicin without interfering with the drug’s anticancer efficacy, a question that remains to be directly tested.

As with any preclinical study, important caveats apply. The work was conducted in rats and in a cardiomyoblast cell line, and the chronic doxorubicin model, while well established, does not capture every dimension of human cardiotoxicity, including the contributions of patient age, comorbidities, and concurrent cancer therapies. The DRP1 overexpression experiments showed only partial reversal of shikonin’s effects, which the authors themselves frame as indicating that DRP1-related mitochondrial dysregulation contributes to, but does not fully account for, the compound’s protection. Human dosing, safety, and drug-interaction studies would be essential before any clinical translation. Nevertheless, the convergence of functional, histological, biochemical, and mechanistic evidence in this study makes a compelling case that shikonin attenuates doxorubicin-induced myocardial injury, senescence, and fibrosis through improved redox and mitochondrial homeostasis, and it identifies the DRP1-driven fission pathway and the p53/p21 senescence axis as promising targets for the next generation of cardioprotective strategies in oncology.

Subject of Research: Shikonin's cardioprotective effects against doxorubicin-induced myocardial senescence and fibrosis via mitochondrial and redox homeostasis

Article Title: Shikonin attenuates doxorubicin-induced myocardial senescence and fibrosis in association with improved redox and mitochondrial homeostasis

Article References: Ren, G.-Q., He, M.-L., Guo, Y.-Q., Li, Z.-X., Liu, H.-J., Li, J., Zhang, J., & Yang, J. (2026). Shikonin attenuates doxorubicin-induced myocardial senescence and fibrosis in association with improved redox and mitochondrial homeostasis. Molecular Biology Reports, 53(1), Article 1649. https://doi.org/10.1007/s11033-026-12790-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12790-y

Keywords: shikonin, doxorubicin, cardiotoxicity, mitochondrial dynamics, DRP1, cellular senescence, p53/p21 signaling, myocardial fibrosis, oxidative stress, cardioprotection, naphthoquinone, H9c2 cells

The significance of coenzyme A in cardiac biology is difficult to overstate. This small, vitamin B5-derived cofactor sits at the crossroads of virtually every energy-generating pathway in the cell, shuttling acyl groups into the mitochondria for fatty acid oxidation, feeding the tricarboxylic acid cycle, and enabling the synthesis and breakdown of countless metabolites. Without adequate coenzyme A, the heart’s metabolic machinery grinds toward inefficiency. In the failing heart, a condition long recognized as one of profound metabolic inflexibility, the supply and utilization of this cofactor become compromised, leaving cardiomyocytes unable to fully exploit the fuels available to them. The failing heart, in this sense, is not merely an overworked pump but an energy-starved engine running on a degraded fuel system.

The pivotal evidence comes from a study by Forelli and colleagues published in Science in 2026, which demonstrated that SGLT2 inhibitors activate pantothenate kinase in the human heart. Pantothenate kinase is the first and rate-limiting enzyme of the coenzyme A biosynthesis pathway, the molecular gatekeeper that controls how much coenzyme A the cell can manufacture from pantothenate, the dietary precursor better known as vitamin B5. By stimulating PANK1, the drugs effectively reopen this gate, boosting coenzyme A availability and, with it, the myocardial metabolic capacity that heart failure erodes. Riccio and Santulli emphasize that PANK1 should now be considered a direct cardiac target of SGLT2 inhibitors, a designation that reframes how the field thinks about these drugs entirely.

What makes this finding particularly provocative is its independence from the drug’s canonical target. SGLT2, the glucose transporter in the kidney that gives the class its name, is barely expressed in cardiomyocytes, which has long puzzled researchers trying to explain why the heart benefits so much. Recent work has reinforced this disconnect: a 2024 study in Circulation Research showed that SGLT2 inhibitors confer benefit in mouse models of heart failure with reduced ejection fraction even in the absence of SGLT2, and a 2026 study in Metabolism identified early metabolic cardiac targets of empagliflozin that operate independently of SGLT2 inhibition. The PANK1–coenzyme A axis now emerges as one of the most concrete candidates for these SGLT2-independent actions, offering a direct biochemical route from drug to heart cell.

The commentary also situates the new discovery within a broader and evolving understanding of how SGLT2 inhibitors reprogram cardiac metabolism. Beyond glucose lowering, the class has been shown to enhance ketogenesis through an unexpected mechanism: rather than simply raising circulating ketone levels by shifting renal handling of glucose, the drugs act as allosteric activators of HMGCS2, the mitochondrial enzyme that catalyzes the rate-limiting step of ketone body synthesis, as reported in the Journal of Clinical Investigation in 2026. Meanwhile, the randomized, controlled EMPA-VISION trial assessed cardiac energy metabolism in patients with heart failure taking empagliflozin and provided a rigorous human window into how the drug reshapes myocardial energetics. Together, these lines of evidence paint a picture of a drug class that acts as a broad-spectrum metabolic modulator rather than a single-target agent.

Viewed through this lens, the cardioprotective portfolio of SGLT2 inhibitors begins to look like a coordinated campaign on multiple metabolic fronts. The PANK1 activation restores the coenzyme A supply needed to import and oxidize fatty acids, the heart’s preferred fuel. The HMGCS2 activation boosts ketone production, providing an oxygen-efficient alternative substrate. Additional studies, including work in frail hypertensive and diabetic patients published in Hypertension, have documented improved endothelial function and reduced mitochondrial oxidative stress with empagliflozin, extending the metabolic story to the vasculature. Each mechanism addresses a different facet of the energetic deficit that defines the failing heart, and together they may explain why the clinical benefits of these drugs have been so consistent across patient populations with and without diabetes.

The therapeutic implications of targeting the PANK1–coenzyme A axis extend well beyond explaining an existing drug class. If restoring coenzyme A biosynthesis can rescue myocardial metabolic capacity, then PANK1 itself becomes a druggable node for heart failure therapy, potentially separable from SGLT2 inhibition altogether. This matters for patients who cannot tolerate SGLT2 inhibitors or who face contraindications, and it opens the door to rational combination strategies in which metabolic restoration is pursued deliberately rather than as a side effect of glucose handling. It also invites a re-examination of nutritional and pharmacological approaches to pantothenate metabolism in cardiac disease, a corner of cardiology that has received comparatively little attention despite the centrality of coenzyme A to heart function.

There are, of course, important questions that remain before the laboratory insight can be translated into bedside practice. The precise dose–response relationship between SGLT2 inhibitor exposure and PANK1 activation in the human heart, the time course over which coenzyme A restoration translates into functional improvement, and the extent to which this mechanism contributes to benefit relative to hemodynamic and neurohormonal effects all require further study. Human trials such as EMPA-VISION have begun to map the metabolic consequences of treatment in patients, but directly interrogating the PANK1 pathway in the myocardium remains a technical challenge. Riccio and Santulli’s commentary serves as both a synthesis of the current evidence and a roadmap for the experiments that will determine whether the coenzyme A story holds up as a central pillar of cardioprotection.

For a field that has spent two decades chasing the secret behind one of medicine’s most serendipitous successes, the identification of a direct cardiac target offers a rare moment of clarity. The heart fails, in large part, because it runs out of usable energy, and a drug class that replenishes the cofactor at the very heart of energy metabolism addresses the disease at its biochemical root. Whether PANK1 activation proves to be the dominant mechanism or one strand in a richer web of metabolic actions, the convergence of evidence from human hearts, mouse models, and clinical trials suggests that the era of thinking about SGLT2 inhibitors as mere glucose-lowering agents is definitively over. What began as a diabetes treatment has become a master key to cardiac metabolism, and the PANK1–coenzyme A axis may be one of its most important locks.

Subject of Research: Cardioprotective mechanisms of SGLT2 inhibitors through PANK1-mediated coenzyme A restoration in heart failure

Article Title: Beyond glucose lowering and ketogenesis: unveiling new cardioprotective mechanisms of SGLT2 inhibitors

Article References: Riccio, A., & Santulli, G. (2026). Beyond glucose lowering and ketogenesis: unveiling new cardioprotective mechanisms of SGLT2 inhibitors. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-026-01357-w

Image Credits: AI Generated

DOI: 10.1038/s41569-026-01357-w

Keywords: SGLT2 inhibitors, heart failure, PANK1, coenzyme A, cardiac metabolism, pantothenate kinase, ketogenesis, empagliflozin, HMGCS2, mitochondria, cardioprotection, metabolic flexibility

The breadth of melatonin’s reported activities is striking. Beyond its sedative effect, the review catalogs antitumor, immunomodulatory, antioxidant, antihypertensive and cardioprotective actions, along with roles in regulating body weight, gastrointestinal function, reproduction and thermoregulation. Part of this versatility is chemical: melatonin crosses biological membranes freely and reaches nearly every compartment of the cell. Part of it is signaling: melatonin binds specific G-protein-coupled receptors, but it also engages intracellular pathways that govern whether a cell survives stress, divides, inflames or dies. The question the review tackles is which of these pathways best explains the hormone’s pharmacological reach, and its answer centers on SIRT1, the most intensively studied member of the mammalian sirtuin family.

SIRT1 is a nicotinamide adenine dinucleotide, or NAD+, dependent deacetylase, meaning it removes acetyl chemical groups from proteins only when the metabolic cofactor NAD+ is available. This makes the enzyme a direct sensor of cellular energy status, because NAD+ levels rise and fall with nutrient availability, fasting and metabolic strain. SIRT1 shuttles between the cytoplasm and the nucleus, where it strips acetyl groups from histones, the spools around which DNA is wound, and from a growing list of non-histone proteins including the tumor suppressor p53, the transcription factors FoxO and NF-κB, and the mitochondrial regulator PGC-1α. Through these targets, SIRT1 influences cell survival, metabolism, growth, aging and resistance to stress, which is precisely the portfolio of processes that goes wrong in chronic disease.

The review’s central claim is that melatonin can modulate SIRT1 activity, and that this modulation in turn shapes four fundamental cellular responses: inflammation, oxidative stress, apoptosis and autophagy. In inflammatory bowel disease, for example, recent work cited in the review shows that melatonin restores the intestinal mucosal barrier by activating a SIRT1-LKB1-pAMPK signaling axis. In autoimmune and sepsis models, SIRT1 deacetylates components of the NF-κB pathway and the NLRP3 inflammasome, damping the production of tumor necrosis factor alpha, interleukin-1 and other inflammatory mediators. Because NF-κB sits upstream of cyclooxygenase-2 and inducible nitric oxide synthase, a single deacetylation event can cascade into a broad suppression of the inflammatory program.

The cardiovascular evidence is among the most developed. In type 2 diabetic rats, reduced SIRT1 signaling worsens myocardial ischemia-reperfusion injury, and melatonin treatment restores protection through the enzyme. Melatonin receptor-mediated cardioprotection against ischemia-reperfusion has likewise been traced to SIRT1. In diabetic hearts, melatonin prevents Drp1-mediated mitochondrial fission, the excessive fragmentation of mitochondria that starves cardiomyocytes of energy, via the SIRT1-PGC-1α pathway, and activation of the SIRT1-PGC-1α-SIRT3 cascade protects against mitochondrial dysfunction in isoproterenol-induced myocardial injury. The chemotherapy drug doxorubicin, notorious for causing heart damage, appears less toxic when melatonin activates the Sirt1/Nrf2 pathway, inhibiting oxidative stress, pyroptosis and apoptosis. In sepsis-induced cardiac dysfunction, melatonin acts through SIRT1 to regulate both apoptosis and autophagy, including SIRT1-mediated deacetylation of beclin-1 and of the transcription factor TFEB, which orchestrates lysosomal clearance of damaged material.

The kidney tells a parallel story. Melatonin attenuates acute kidney ischemia-reperfusion injury in diabetic rats by activating the SIRT1/Nrf2/HO-1 axis, a canonical antioxidant pathway in which Nrf2, once deacetylated and stabilized, switches on heme oxygenase-1 and other detoxifying genes. In diabetic kidney disease, protection runs through SIRT1/NLRP3 signaling, curbing the inflammasome-driven inflammation that scars the filtering units of the kidney. Melatonin also prevents acute kidney injury in severely burned rats via SIRT1 activation, and in cadmium-induced proximal tubular injury it preserves mitochondrial function by blocking fission through SIRT1-PGC-1α. Perhaps most intriguingly, melatonin lowers the abundance of hypoxia-inducible factor 1α in human proximal tubular cells by preventing its deacetylation by sirtuin 1, a reminder that SIRT1’s effects are not uniformly protective but context-dependent, and that melatonin’s modulation of the enzyme can push it in either direction depending on the tissue and insult.

In the liver, the review highlights melatonin’s effects on non-alcoholic fatty liver disease, a condition now affecting a substantial share of the world’s overweight and obese population. Melatonin’s benefits in fatty liver models are linked to the microRNA-34a-5p/Sirt1 axis and to autophagy, the cellular recycling system that clears lipid droplets and damaged organelles. In hypercholesterolemic mice, melatonin’s modulation of sirtuin-1 attenuates liver injury. The enzyme also mediates protection against toxic exposures: melatonin inhibits benzo(a)pyrene-induced apoptosis in mouse liver through the miR-34a/Sirt1/autophagy pathway, and it attenuates arsenic-induced liver injury through Nrf2/HO-1, apoptosis and miR-34a/Sirt1/autophagy routes. In alcoholic liver injury, melatonin-induced SIRT1 disrupts the cereblon-YY1-CYP2E1 signaling pathway, reducing the oxidative metabolism of alcohol that generates damaging free radicals, while in sepsis-induced liver injury melatonin activates SIRT1/STAT3 signaling to rescue dysregulated gluconeogenesis.

The reproductive findings may prove the most clinically provocative. In polycystic ovary syndrome, melatonin enhances SIRT1 expression in granulosa cells to ameliorate excessive PINK1/Parkin-mediated mitophagy and to protect mitochondrial membranes through PDK1/Akt signaling, and it attenuates Drp1-driven mitochondrial fission through SIRT1 upregulation. The ROS/SIRT1/STAR axis has been identified as a target through which melatonin corrects atrazine-induced mitochondrial dysfunction and steroid disorders in granulosa cells. In oocytes, melatonin protects against chronic stress-induced meiotic defects by regulating SIRT1, and follicular fluid insufficiency of melatonin has been proposed as a reversible cause of the chromosomal abnormalities seen in oocytes of advanced maternal age. On the male side, melatonin protects mouse testes from palmitic acid-induced lipotoxicity in a SIRT1-dependent manner, ameliorates diabetic impairment of Leydig cell steroidogenic function through SIRT1 activation, and modulates SIRT1 to counter LPS-induced testicular nitro-oxidative stress and inflammation. Human trials add a translational note: melatonin supplementation improved semen parameters in men with idiopathic infertility in a triple-blind randomized placebo-controlled trial, and melatonin therapy added benefit to varicocelectomy in a double-blind trial, with epigenetic effects in a varicocele rat model mediated by silent information regulator 1.

The musculoskeletal section rounds out the picture. In osteoarthritis, melatonin exerts cytoprotective and anti-inflammatory effects in human chondrocyte cells and in rabbit models via the SIRT1 pathway, prevents cartilage matrix degradation by inhibiting NF-κB through SIRT1, and regulates chondrocyte hypertrophy and apoptosis through the Sirt1/P53/P21 axis. It also promotes sirtuin 1 expression to inhibit the IRE1α-XBP1S-CHOP branch of the unfolded protein response, reducing endoplasmic reticulum stress-mediated apoptosis in chondrocytes. In intervertebral disc degeneration, melatonin protects vertebral endplate chondrocytes against apoptosis and calcification via the Sirt1-autophagy pathway and holds promise through inhibiting M1-type macrophage polarization via SIRT1/Notch signaling. Even in cancer the relationship is bidirectional: whereas SIRT1 activation generally protects healthy tissue, melatonin’s antitumor activity in human osteosarcoma cells has been attributed to SIRT1 inhibition, underscoring that the same enzyme can be friend or foe depending on cellular context.

The authors are careful to note the limits of the evidence. Despite the breadth of preclinical data, they write that evidence regarding the role of SIRT1 in melatonin’s effects remains limited, and much of what is known comes from cell cultures and animal models rather than definitive human trials. Whether melatonin reliably activates SIRT1 in human tissues at supplement doses, and whether SIRT1 is necessary rather than merely correlated with the hormone’s benefits, will require pharmacological inhibitors, genetic models and properly powered clinical studies. Still, the synthesis is compelling in its coherence: a hormone produced by a tiny gland in the brain, acting through an NAD+-dependent enzyme that links metabolism to gene expression, appears to coordinate protective programs across organs as different as the heart, kidney, liver, ovary and joint. If future work confirms SIRT1 as the common mediator, melatonin’s humble reputation as a sleep aid may give way to something far more interesting, a cheap and safely tolerated molecule that tunes the body’s central longevity machinery.

Subject of Research: The role of the SIRT1 signaling pathway in the therapeutic effects of melatonin across disease models

Article Title: The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway

Article References: Vahidinia, Z., Behdarvandy, M., Azami Tameh, A., Barati, S., & Yasamian, A. (2026). The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway. Molecular Biology Reports, 53(1), Article 1667. https://doi.org/10.1007/s11033-026-12815-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12815-6

Keywords: melatonin, SIRT1, sirtuins, NAD+, deacetylation, oxidative stress, autophagy, apoptosis, cardioprotection, diabetic cardiomyopathy, non-alcoholic fatty liver disease, polycystic ovary syndrome

The scientific foundation of that leap rests on a remarkably rich phytochemical profile. Arjuna bark contains four major classes of bioactive compounds: triterpenoids including arjunic acid, arjunolic acid, arjunetin, arjungenin, and arjunglucosides; fifteen varieties of tannins, among them casuarinin and punicalagin; flavonoids such as luteolin, quercetin, kaempferol, and baicalein; and phenolic acids like gallic and ellagic acid. Together with minerals including copper, zinc, magnesium, and calcium, these constituents underpin a pharmacological portfolio spanning anti-tumoral, anti-inflammatory, antioxidant, antimicrobial, hypolipidaemic, wound-healing, cardioprotective, and anti-diabetic activities. But the review also reveals a crucial technical caveat: the chemistry is not uniform. Stem bark is the principal source of arjunic and arjunolic acids, while root bark yields distinct glycosides, and HPLC sampling across Indian geographic locations found substantial site-to-site variation in arjungenin and arjunic acid content. Extraction method matters too—alcoholic solvents efficiently pull out arjunic acid while hexane does not, and ultrasound-assisted extraction preserves more phenolics and flavonoids than conventional heating. Different solvents yielded only nine phytochemicals in common out of thirty identified compounds, meaning that two Arjuna products on a shelf may be chemically different medicines.

Nowhere is the molecular story more striking than in cancer research, where Arjuna’s compounds converge on a shared lethal strategy against malignant cells: mitochondrial, ROS-driven, caspase-mediated apoptosis. In non-small-cell lung cancer lines A549 and H460, arjunic acid triggers apoptotic body formation, PARP cleavage, and a JNK-dependent endoplasmic reticulum stress pathway involving IRE1α, ATF4, and CHOP—when researchers blocked JNK with the inhibitor SP600125, the cytotoxicity vanished, confirming the pathway’s centrality. Casuarinin, a hydrolysable tannin from the bark, tells an equally elegant story of molecular flexibility. In A549 lung cancer cells it induces G0/G1 cell-cycle arrest through p53 upregulation and p21/WAF1 induction, yet in MCF-7 breast cancer cells it elevates p21 without touching p53, reaching the same endpoint through a different door. The compound also activates the extrinsic Fas/FasL and caspase-8 pathway and shows anti-herpes activity against HSV-2 by disrupting viral glycoproteins C and D, blocking viral entry at concentrations with no toxicity to kidney cells.

Animal models have pushed the evidence beyond the dish. Arjunolic acid reduced tumor growth in Ehrlich ascites carcinoma mice by suppressing TGF-β1 signaling, restoring immune balance, and activating caspase-3, while ethanolic bark extract prolonged survival in Dalton’s lymphoma mice by 60 to 87.5 percent depending on dose and extended lifespan by roughly 35 percent in a solid tumor model. In a chemoprevention twist, oral administration of the extract at 500 milligrams per kilogram reduced tumor incidence and burden in hamsters exposed to the carcinogen DMBA, normalizing antioxidant status along the way. The most futuristic branch of this work involves nano-engineering: self-assembled arjunolic acid forms liposome-like vesicles that selectively enter cancer cells and kill them through a TNF-α-driven, ROS-dependent pathway; biosynthesized silver and selenium nanoparticles from the bark showed potent cytotoxicity against HepG2, PC3, and MCF-7 cells while sparing normal Vero cells; and copper-silver multi-walled carbon nanotube hybrids extended the approach across multiple cancer lines. The honest limitation, the review stresses, is that none of these nano-formulations has been tested for pharmacokinetics, toxicity, or safety in living organisms, and no human cancer trial of Arjuna exists at all.

Cardiovascular protection, by contrast, is where Arjuna’s evidence is strongest—and where its traditional reputation as a heart remedy finds its most concrete modern support. Across three distinct toxic-injury models, the extract and its constituents consistently shield cardiomyocytes through antioxidant and anti-apoptotic mechanisms. Against cobalt chloride-induced hypoxia in H9c2 heart cells, pretreatment restored viability and rebalanced the Bax/Bcl-2 apoptotic switch. Against doxorubicin, the chemotherapy drug whose cardiotoxicity limits its clinical use, arjunolic acid suppressed p38/JNK-driven Bax translocation, preserved mitochondrial membrane potential, and prevented cytochrome c release—a finding that raises the possibility of Arjuna as a cardioprotective adjunct for patients undergoing chemotherapy. Against isoproterenol-induced myocardial necrosis, the extract elevated antioxidant enzymes and blocked JNK/c-jun signaling. Deeper mechanistic work revealed that arjunolic acid acts as a direct PPARδ agonist that also inhibits TAK1, blocking non-canonical TGF-β signaling to regress cardiac fibrosis—when researchers silenced PPARδ, the anti-fibrotic effect disappeared entirely. In atherosclerosis-prone ApoE-deficient mice, aqueous extract downregulated CD36, MMP-9, VCAM-1, and ICAM-1 while activating cholesterol-efflux regulators PPAR-γ and LXR-α, reducing plaque burden with effects the study reported as comparable to atorvastatin, though from a single animal experiment rather than a head-to-head trial.

The protective reach extends well beyond the heart. Arjunolic acid guards the liver against acetaminophen overdose by inhibiting CYP2E1, the enzyme that converts the painkiller into its toxic metabolite NAPQI, and against cadmium, arsenic, and fluoride by restoring glutathione balance and antioxidant enzymes. In the kidney, it counters cisplatin nephrotoxicity by suppressing NF-κB, TGF-β, and caspase cascades, while aqueous extract reduces calcium oxalate crystallization and crystal adhesion to renal epithelial cells—the underlying process of kidney stones—with four novel antiurolithiatic proteins recently identified from the bark. Neuroprotection is emerging too: in rat stroke models the extract reduced infarct volume and preserved blood-brain barrier tight-junction proteins, and at simulated high altitude it reversed hypobaric hypoxia-induced renal and cerebrovascular damage through an atrial natriuretic peptide-mediated mechanism. In diabetes models, Arjuna works on both ends of the metabolic problem—boosting insulin availability and IRS-1/PI3K/Akt signaling while directly inhibiting DPP-IV with activity close to the drug sitagliptin, plus α-amylase and α-glucosidase to blunt post-meal glucose spikes, all while protecting the pancreas, retina, and heart from hyperglycemic injury through AMPK-mTOR-HO-1 autophagy and NF-κB/MAPK suppression.

Human clinical data, though limited, is genuinely encouraging and concentrated in cardiology. A double-blind trial in 116 coronary artery disease patients found that 500 milligrams of extract twice daily for three to six months lowered triglycerides and VLDL cholesterol more effectively than atorvastatin alone while suppressing TNF-α and IL-6 and raising IL-10. A long-term observational study followed 35 chronic CAD patients taking the extract alongside standard therapy for four to five years with no adverse effects on blood, liver, or kidney parameters, no hospitalizations, and no deaths—though without a randomized control group it cannot isolate the herb’s contribution. In heart failure, the results diverge instructively: a tiny 12-patient trial in severe refractory cases reported improved ejection fractions sustained over 28 months, but a larger, better-powered 100-patient trial found no ejection-fraction benefit, instead showing gains in exercise tolerance, quality-of-life scores, and red-cell antioxidant markers. Additional trials reported reduced ischemic mitral regurgitation after heart attack, improved endothelial function in chronic smokers, improved venous clinical severity in chronic venous insufficiency, and—remarkably—fasting blood sugar and HbA1c reductions comparable to sitagliptin when combined with metformin in type 2 diabetes. A dermatological study even found that a 0.25 percent extract cream cut transepidermal water loss by 46 percent and quadrupled skin moisturization, opening a cosmeceutical frontier.

Food scientists are already translating this pharmacology into edible formats. Microencapsulated Arjuna extract blended into a vanilla chocolate milk drink significantly reduced triglycerides, total cholesterol, LDL, and VLDL in hypercholesterolemic rats over a 60-day trial while preserving the beverage’s flavor and sensory properties. Seven percent ethanolic bark extract extended the shelf life of ghee several-fold in accelerated oxidation testing, and graded concentrations of the extract in goat meat batter reduced lipid oxidation and spoilage organisms over nine days of storage. In aquaculture, dietary bark powder at 10 grams per kilogram of feed enhanced immune markers in rohu fish over 90 days. Arjuna gum itself has emerged as a natural biopolymer for pH-responsive microbeads and controlled-release gels, and calcium-alginate edible films containing the extract improved the oxidative and microbial stability of chevon sausages—positioning the tree as both ingredient and packaging technology.

Safety data are reassuring but incomplete, and the review is candid about the gaps. Short-term toxicity is low: hydroalcoholic bark extract showed no mortality at 2,000 milligrams per kilogram and no harmful effects at 1,000 milligrams per kilogram daily for 28 days, and both hydroalcoholic and methanolic bark extracts were negative in Ames and chromosomal aberration tests. Yet a methanolic leaf extract had an LD50 of 900 milligrams per kilogram, and alcoholic bark extract reduced testicular steroidogenic activity and testosterone in male rats after 21 days—findings that cannot be extrapolated across preparations. Pharmacokinetic studies show the extracts inhibit CYP3A4, CYP2D6, and CYP2C9 in vitro, with whole-extract composition, not individual triterpenoids, driving the interaction risk, and a nanosuspension formulation boosted oral bioavailability 1.33-fold. The path forward, the authors argue, requires larger multi-center placebo-controlled trials with standardized, chemically characterized formulations, harmonized endpoints, nanotechnology and microencapsulation for bioavailability, and multiomic approaches enabling precision nutrition. If those pieces come together, a tree worshipped in ancient Sanskrit medical texts may finally earn its place not just in tradition, but in the evidence-based architecture of modern food and health.

Subject of Research: Phytochemistry, pharmacology, clinical evidence, and nutraceutical applications of Terminalia arjuna bark

Article Title: Harnessing Terminalia arjuna in Next Generation Phytomedicine: Cutting Edge Nutraceutical Trends Shaping Food and Health

Article References: Banerjee, I., Nazeerulla, F., Paul, M. K., Bhutia, S. K., Basu, D., & Mukhopadhyay, S. (2026). Harnessing Terminalia arjuna in Next Generation Phytomedicine: Cutting Edge Nutraceutical Trends Shaping Food and Health. Food Science & Nutrition, 14(10), Article e72352. https://doi.org/10.1002/fsn3.72352

Image Credits: AI Generated

DOI: 10.1002/fsn3.72352

Keywords: Terminalia arjuna, Ayurveda, phytomedicine, nutraceuticals, cardioprotection, arjunolic acid, arjunic acid, casuarinin, functional foods, antioxidants, nanoparticles, clinical trials